Evidence map›Paper›PMID 43006802›Full record

ArticleGut microbes2026

Impact of

Yi-Lei Peng, Ya-Yi Xiao, Si-Jin Yin, Hong-Hao Zhou, Wei Zhang, Peng Zhu, Qing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Lei PengKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Ya-Yi XiaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, ChangSha, China.
Si-Jin YinKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Hong-Hao ZhouKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Wei ZhangKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Peng ZhuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, ChangSha, China.
Qing LiKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.ORCID 0000-0002-1787-4180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota is increasingly recognized as a regulator of host lipid metabolism, yet the specific strains and effector metabolites driving hyperlipidemia remain poorly defined. Here, we identified

Indexed as

EubacterialesLipid MetabolismAnimalsBile Acids and SaltsCholesterolDiet, High-FatFecesFemaleGastrointestinal MicrobiomeHumansHyperlipidemiasLiverMaleMiceMice, Inbred C57BLBile Acids and SaltsCholesterolbile acidgut microbiotaHyperlipidemialipid metabolismRuminococcus gnavus

Identifiers

PMID43006802
PMCPMC13757622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.